Table 2.
Tamoxifen pharmacokinetics with or without CBD.
| Pharmacokinetic parameters (N = 15) | Tamoxifen monotherapya | Tamoxifen + CBDa | Relative difference (%) with vs without CBD (90% CI) |
|---|---|---|---|
| Tamoxifen | |||
| AUC0–24h (nmol ∙ h ∙ L−1) | 7100 (669) | 6900 (622) | −2.8% (−7.7, +2.4%) |
| Cmin | 272 (67) | 252 (64) | −7.2% (−14.1, +0.4%) |
| Cmax | 397(69) | 392 (61) | −1.2% (−8.2, +6.4%) |
| Endoxifen | |||
| AUC0–24h (nmol ∙ h ∙ L−1) | 621 (22) | 542 (18) | −12.6% (−18.7, −6.1%) |
| Cmin | 28 (22) | 23 (20) | −18.2% (−23.4, −12.7%) |
| Cmax | 33 (20) | 27 (17) | −16.3% (−20.7, −11.7%) |
AUC area under the curve, Cmin minimum plasma concentration, Cmax maximum plasma concentration.
aGeometric mean (coefficient of variation %).